Melanotan II

What is Melanotan II?

Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH). It was originally developed at the University of Arizona as a potential sunless tanning agent. It activates melanocortin receptors broadly, which is why it affects multiple systems including skin pigmentation, sexual function, and appetite. The FDA has issued explicit warnings against the use of Melanotan II, citing safety concerns including unpredictable pigmentation changes, mole changes that may complicate skin cancer screening, and reports of serious adverse events. It is not recommended for any use outside of supervised research settings.

What Melanotan II Is Investigated For

Melanotan II is used almost exclusively in the research-chemical and underground market for UV-independent skin tanning, with secondary claims around sexual arousal and appetite suppression arising from its broad non-selective activation of MC1R, MC3R, MC4R, and MC5R. The strongest evidence is mechanistic — melanocortin receptor pharmacology is well-characterized, and early Phase 1 work demonstrated both pigmentation and spontaneous-erection effects (the latter of which led to the development of bremelanotide/PT-141 as a more MC4R-selective FDA-approved derivative). MT-II itself has never advanced through formal drug development, is not approved anywhere, and the FDA, UK MHRA, and Australia's TGA have all issued public warnings against its use. The safety concerns are substantial and specific rather than speculative: case reports document rhabdomyolysis, renal infarction, eruptive nevi, concerning darkening of existing moles that can complicate melanoma screening, at least one case of oral mucosal melanoma in a nasal-spray user, a 2026 case of five synchronous primary cutaneous melanomas-in-situ in an MT-II user with concurrent tanning-bed and anabolic-hormone exposure (JAAD Case Reports 2026), and paradoxical depigmentation reported in a patient with pre-existing autoimmune skin disease (Clin Exp Dermatol 2026) — indicating the pigmentation response is bidirectional and unpredictable rather than uniformly darkening. Analytical work on the black-market supply adds a second, separate problem: injectable vials bought from three online shops, every one labeled 10 mg, assayed at 4.32–8.84 mg of actual melanotan II, with unidentified impurities of 4.1–5.9% in the products from two of the three shops, and forensic laboratories examining MT-II and bremelanotide seized from the performance-and-image-enhancing-drug market have had to characterize those samples without reference standards at all — so dose, purity and even identity are things nobody buying from this market can actually verify. This is one of the higher-risk compounds in the peptide conversation, and the tanning-without-UV framing does not carry the safety implications it is often assumed to.

History & Discovery

Melanotan II was synthesized in the 1980s at the University of Arizona by Mac Hadley, Victor Hruby, and colleagues, who were working on structure-activity relationships of α-melanocyte-stimulating hormone (α-MSH) and related melanocortin peptides. The scientific goal was to develop a stable, potent α-MSH analog that could drive melanogenesis — the skin's natural tanning process — without the instability of native α-MSH. The team designed a cyclic heptapeptide through lactam bridge cyclization and several amino acid substitutions; the resulting molecule, Melanotan II (MT-II), was substantially more potent than native α-MSH at melanocortin receptors and proved to be a broad agonist across MC1R, MC3R, MC4R, and MC5R. Early Phase 1 studies in the 1990s demonstrated skin pigmentation changes and spontaneous erections — the latter being an unexpected MC4R-mediated effect that eventually led to the development of bremelanotide (PT-141), a more MC4R-selective derivative that was FDA-approved for hypoactive sexual desire disorder in premenopausal women in 2019. MT-II itself was never advanced through formal drug development. Instead, it leaked into the underground and research-chemical market in the 2000s, marketed as an injectable tanning agent and later as an enhancement compound. Regulatory bodies in multiple jurisdictions — including the FDA, UK MHRA, and Australia's TGA — have issued public warnings and, in several cases, taken enforcement action against unlicensed MT-II sales. The drug has been linked to multiple case reports of adverse events including rapid mole darkening, eruptive nevi, rhabdomyolysis, renal infarction, and concerning changes to oral mucosal melanocytes in nasal-spray users. MT-II remains unapproved anywhere in the world. A 2026 International Journal of Dermatology perspective from Sidhu, Konig, Yu-Corpuz, and Corpuz argued that social-media platforms and the 'looksmaxxing' subculture — an appearance-optimization movement often intertwined with body dysmorphic disorder — have driven a renewed surge of unregulated MT-II use among young adults, framing the accumulating dermatologic case-report base as an emerging public-health rather than isolated-toxicology signal.

How It Works

Melanotan II activates the same receptors that natural melanocyte-stimulating hormone uses. These receptors control skin pigmentation (tanning), sexual arousal, and appetite. Because it activates multiple receptor subtypes, it has broad effects — which is both its appeal and its risk.

Melanotan II is a cyclic heptapeptide analog of α-MSH that acts as a non-selective agonist at MC1R (pigmentation), MC3R (energy homeostasis), MC4R (sexual function, appetite), and MC5R (exocrine function). MC1R activation stimulates melanogenesis in melanocytes, increasing eumelanin production. The broad receptor profile explains its diverse physiological effects but also contributes to its side effect profile.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Melanotan II:

• 01Long-term safety of chronic or repeated melanocortin agonism — no prospective multi-year safety data exists in any indication.
• 02Skin cancer risk — the combination of chronic melanocyte stimulation, documented eruptive nevi, and mole darkening raises a concern about melanoma risk that has not been addressed by rigorous epidemiologic study. The case-report base is growing and now includes an oral mucosal melanoma case in a nasal-spray user, a 2026 case of five synchronous primary cutaneous melanomas-in-situ (JAAD Case Reports) with concurrent tanning-bed and anabolic-hormone exposure, and paradoxical depigmentation in a patient with pre-existing autoimmune skin comorbidities — causal attribution remains complicated by confounders, but the accumulating pattern is no longer 'theoretical concern with no cases.'
• 03Cardiovascular effects — case reports of renal infarction, blood pressure changes, and ischemic events exist but have not been systematically characterized.
• 04Product quality and identity in research-chemical supply — analytical studies have found substantial deviations from labeled content; the clinical consequences of using mislabeled or contaminated products have not been quantified.
• 05Neuropsychiatric effects — MDMA-like empathogenic reports exist in online user communities but have not been prospectively studied; the neurotransmitter systems involved are not fully mapped.
• 06Optimal receptor selectivity — MT-II's broad MC1–MC5 activation profile produces diverse effects; whether more selective analogs (bremelanotide for MC4R, afamelanotide for MC1R) can capture specific benefits without broader side-effect burden is partially but not fully answered.

Forms & Administration

Melanotan II is typically administered via subcutaneous injection. It is not FDA-approved for any indication and the FDA has issued public warnings against its use. Due to safety concerns — including serious adverse event reports and risks to skin cancer screening — its use is not recommended outside of supervised clinical research. Never self-administer without clinician oversight.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

MT-II is not FDA-approved for any indication. The FDA, UK MHRA, and Australia's TGA have issued public warnings against its use. The doses described above reflect what is documented in research-chemical use, not clinical recommendation. Any use outside of supervised research is associated with meaningful safety concerns that are not fully characterized.

Timeline of Effects

Common Questions

Who Melanotan II Is NOT For

Drug & Supplement Interactions

Formal drug interaction data for MT-II is essentially absent because the compound has never been through regulated clinical development. The most clinically relevant theoretical concerns involve cardiovascular co-medications — MT-II has been linked in case reports to renal infarction and can raise blood pressure, so combinations with vasoconstrictive agents (including decongestants), stimulants, and poorly controlled hypertension regimens represent a theoretical concern. Co-use with other melanocortin agonists, including bremelanotide (PT-141), could produce additive effects on blood pressure and receptor-mediated side effects. The empathogenic effects some users report overlap with serotonergic signaling, raising a theoretical concern about combinations with SSRIs, MAOIs, MDMA, or other serotonergic drugs — though this interaction has not been rigorously characterized. More broadly, because research-chemical product quality is inconsistent, interactions attributed to MT-II in case reports may reflect contaminants or misidentified compounds rather than MT-II itself. Anyone using MT-II who is on chronic medications should disclose the use to their prescribing clinician.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions